Fennec announces Univ of Arizona investigator-sponsored study of PEDMARK in AYA & adult cisplatin patients

FENNEC PHARMACEUTICALS INC.

Phase I/II study by University of Arizona Cancer Center to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in head and neck and testicular cancer patients.
Study builds on two other recent investigator-initiated trials: Tampa General Hospital (Mar 2026) and City of Hope (Dec 2025) in AYA and adult populations.
Fennec CMO states data will support broader clinical adoption and potential label expansion for PEDMARK beyond pediatric approval.
PEDMARK is currently approved for pediatric patients with localized non-metastatic solid tumors and has NCCN 2A recommendation for AYA patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.